ViaCyte, Inc. Company Profile

18:23 EST 21st November 2017 | BioPortfolio

News Articles [6 Associated News Articles listed on BioPortfolio]

ViaCyte to Present at Upcoming Scientific Meetings on Diabetes Research

SAN DIEGO, Sept. 7, 2017 /PRNewswire/ -- ViaCyte, Inc., a privately-held, leading regenerative medicine company, today announced upcoming scientific presentations.  ViaCyte is developing nov...

ViaCyte to Present at Upcoming Investor and Partnering Events in October

SAN DIEGO, Oct. 4, 2017 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, today announced upcoming company presentations at the Cell and Gene Meeting on the Mesa and ...

ViaCyte Awarded New CIRM Grant to Support Clinical Trial of PEC-Direct Product Candidate for High-Risk Type 1 Diabetes

SAN DIEGO, Sept. 28, 2017 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, today announced that the California Institute for Regenerative Medicine (CIRM) approved a ...

ViaCyte Selected as a Finalist for CONNECT's 30th Annual Most Innovative New Product Awards

SAN DIEGO, Sept. 21, 2017 /PRNewswire/ -- Today, ViaCyte announced that its PEC-Direct™ product candidate has been selected as one of three finalists for CONNECT's Most Innovative New Product A...

Treatment begins in trial of islet cell replacement therapy

The first participants have been treated with a novel islet replacement therapy in a new clinical trial, according to a press release from ViaCyte. The islet replacement cell therapy (PEC-Direct, Vita...

ViaCyte Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 28082017] Prices from USD $250

SummaryViaCyte Inc ViaCyte, formerly Novocell, Inc. is a regenerative medicine company that focuses on the development of cell replacement therapies for the treatment of diabetes. The company's pipeli...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Safety and Efficacy of Freezing and Thawing of Human Eggs in Assisted Reproductive Technology

The purpose of this study is to determine the effectiveness of the ViaCyte media for freezing and thawing human eggs for future use in assisted reproductive technology.

More Information about "ViaCyte, Inc." on BioPortfolio

We have published hundreds of ViaCyte, Inc. news stories on BioPortfolio along with dozens of ViaCyte, Inc. Clinical Trials and PubMed Articles about ViaCyte, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ViaCyte, Inc. Companies in our database. You can also find out about relevant ViaCyte, Inc. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record